Core Insights - Anixa Biosciences has received a Notice of Allowance for a patent from the Korean Ministry of Intellectual Property for its breast cancer vaccine technology, marking the first Korean patent for this platform [1] - The patent, titled "Vaccine Adjuvants and Formulations," provides composition of matter protection and is expected to enhance Anixa's global intellectual property portfolio [1] - The company aims to leverage this patent to pursue international commercialization opportunities and potential partnerships with larger pharmaceutical firms [1] Patent and Technology - The newly allowed patent reinforces Anixa's leadership in cancer immunotherapy and complements existing patents in the United States and other jurisdictions [1] - The breast cancer vaccine technology is based on immunizing against human -lactalbumin, a protein associated with lactation, which is aberrantly expressed in certain breast cancer types [1] - Anixa's vaccine has shown promising results in a Phase 1 clinical trial, meeting all major primary endpoints and generating immune responses in 74% of participants [1] Market Context - Breast cancer incidence rates are rising in South Korea, with a notable trend of earlier onset compared to Western nations [1] - Breast cancer remains the most commonly diagnosed cancer among women globally, and there are currently no approved vaccines for its prevention [1] - Anixa's approach aims to transform cancer prevention strategies, particularly for aggressive forms like triple-negative breast cancer [1] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center [1] - The company partners with renowned research institutions to develop vaccines targeting various cancers, including breast and ovarian cancer [1] - Anixa's business model emphasizes collaboration at all stages of development, allowing for the exploration of emerging technologies in complementary fields [1]

Core Insights - Anixa Biosciences will host its 2026 Annual Meeting of Stockholders on March 10, 2026, in a virtual format, which will be open to all interested parties, including non-stockholders [1] - The meeting will feature a corporate update from Anixa's Chairman and CEO, Dr. Amit Kumar, highlighting recent clinical milestones in the oncology pipeline [1] Clinical Progress - The final Phase 1 data from the breast cancer vaccine program met primary endpoints, demonstrating favorable tolerability and immune responses in the majority of participants [1] - Encouraging survival observations were reported in the ongoing Phase 1 ovarian cancer CAR-T trial, along with regulatory approval for substantial dose escalation [1] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes liraltagene autoleucel (lira-cel) for ovarian cancer [1] - The company collaborates with Moffitt Cancer Center to develop a novel CAR-T technology, which utilizes the natural ligand of the FSHR receptor [1] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers [1]

Summary of Anixa Biosciences Fireside Chat Company Overview - **Company**: Anixa Biosciences (NasdaqCM: ANIX) - **Industry**: Biotechnology - **Focus**: Development of CAR T cell therapy for ovarian cancer and a breast cancer vaccine - **Clinical Stage**: Engaged in clinical trials for cancer therapies Key Achievements in 2025 - **Phase 1 Breast Cancer Vaccine Trial**: Completed in collaboration with Cleveland Clinic and U.S. Department of Defense, with data presented in December 2025 [5][6] - **CAR T Therapy Progress**: Significant patient outcomes reported, with advancements in clinical trials and patent approvals [5][6] - **Official Naming**: CAR T therapy received official name approval from domestic and international organizations [6] Upcoming Milestones - **Transition to Phase 2 for Breast Cancer Vaccine**: Requires FDA report submission and discussions, with plans to enroll 80-100 women [7][10] - **Manufacturing Plans**: Working with manufacturers to produce larger vaccine quantities under GLP and GMP conditions [7][8] Financial Overview - **Cash Burn**: $7 million in the last fiscal year, with an expected increase to approximately $8 million for the upcoming year [11][12] - **Cash Reserves**: $15 million cash balance with no debt, providing over two years of operational runway [12][13] CAR T Therapy Developments - **Safety and Efficacy**: Phase 1 trial focused on safety, with promising early efficacy indicators; patients have outlived expected life expectancy [16][18] - **Patient Outcomes**: Some patients lived significantly longer than the median survival of 12 weeks, with one patient living 28 months [18][19] - **Regulatory Approval**: Seeking IRB approval to escalate dosages due to positive safety profile [19] Mechanisms of Action - **Unique Targeting**: CAR T therapy targets a unique protein present only on cancer cells, minimizing effects on healthy tissues [22] - **Anti-Angiogenesis Effect**: Potential destruction of tumor vasculature, enhancing treatment efficacy [23] - **Peritoneal Delivery**: Direct delivery to the peritoneal cavity improves therapy effectiveness and reduces systemic side effects [24] Lymphodepletion Strategy - **Introduction of Lymphodepletion**: Planned to enhance CAR T cell engraftment and proliferation, with careful monitoring of associated risks [31][33] - **Comparative Analysis**: Some cohorts will receive lymphodepletion while others will not, to evaluate its impact on patient outcomes [33] Expectations for 2026 - **Pivotal Year**: Anticipation of significant data from CAR T trials and breast cancer vaccine Phase 2 initiation [36][38] - **Control Arm in Phase 2**: Designed to evaluate the vaccine's efficacy against a control group [38] - **Fiscal Responsibility**: Commitment to maintaining financial prudence while advancing clinical trials [39] Conclusion - **Outlook**: 2026 is expected to be a busy and eventful year for Anixa, with critical data releases and potential partnerships on the horizon [39][40]

Summary of Anixa Biosciences Conference Call Company Overview - **Company**: Anixa Biosciences (NasdaqCM: ANIX) - **Industry**: Biotechnology - **Focus**: Clinical stage biotech company with two early-stage clinical developments: a CAR T cell therapy for ovarian cancer and a breast cancer vaccine program [1][2] Key Points and Arguments Breast Cancer Vaccine Program - The breast cancer vaccine program is designed as both a treatment and prophylactic, focusing on a novel approach targeting a protein expressed only during lactation, which is produced by cancer cells in some breast cancer patients [6][7][8] - The phase one study presented at the 2025 San Antonio Breast Cancer Symposium showed promising results, with the data exceeding expectations and being superior to other cancer vaccines in phase one trials [9][10] Phase One Study Results - The phase one trial involved three cohorts of women: 1. Women with a history of triple-negative breast cancer at high risk of recurrence 2. Women with BRCA mutations who opted for prophylactic mastectomies 3. Women with residual disease post-treatment [10][12][13] - Key findings: - The vaccine was found to be safe with no significant side effects, only mild injection site irritation [11][18] - Strong immune responses were observed in 75% of participants [11][20] - No significant differences in immune response rates among the cohorts [21] Future Clinical Trials - Plans for a phase two study in a neoadjuvant setting, where newly diagnosed breast cancer patients will receive the vaccine alongside standard care (Keytruda) [24][25] - The trial is expected to enroll 80 to 100 women and take approximately two to three years to complete, with data available much sooner [29][31] - The goal is to demonstrate the vaccine's efficacy in reducing tumor burden before surgery, potentially leading to better outcomes and lower recurrence rates [25][27] Corporate Strategy and Partnerships - Anixa aims to establish pharmaceutical partnerships to fund further trials and commercialize the vaccine, reducing reliance on capital markets [28] - The IND has been transferred from Cleveland Clinic to Anixa, allowing the company to sponsor the trial [32] Broader Research Initiatives - Anixa is also advancing preclinical and R&D vaccine programs targeting other cancers, including ovarian, prostate, lung, and colon cancers, with a focus on identifying unique proteins associated with these cancers [34][35] Additional Important Insights - The approach of targeting unique proteins on cancer cells aims to avoid autoimmune responses, which is a significant advantage over traditional cancer vaccine strategies [7][35] - The company is optimistic about the potential for the breast cancer vaccine findings to be replicated in other cancer types, indicating a broader application of their research strategy [34][35]

Core Insights - Anixa Biosciences has completed the transfer of the Investigational New Drug application for its breast cancer vaccine from Cleveland Clinic, becoming the trial sponsor for its future development [1][2] - The company plans to advance the vaccine into a Phase 2 clinical trial after completing enrollment and observing encouraging immune response and safety data in the Phase 1 trial [2][4] - The breast cancer vaccine targets -lactalbumin, a protein that re-emerges in many forms of breast cancer, potentially offering therapeutic and preventive benefits [3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company’s vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, and aims to address various cancers by immunizing against "retired" proteins expressed in certain cancer forms [5] - Anixa's business model involves partnering with renowned research institutions to explore emerging technologies for further development and commercialization [5]

Core Insights - Anixa Biosciences is a clinical stage biotech company focused on developing innovative CAR-T cell therapy for ovarian cancer and a vaccine for breast cancer [2] Company Overview - Anixa is listed on NASDAQ under the ticker ANIX [2] - The company is engaged in the development of additional predevelopment candidates beyond its primary therapies [2] Leadership - Dr. Amit Kumar serves as the Chairman and CEO of Anixa Biosciences [1]

Core Insights - Anixa Biosciences has received a patent for its breast cancer vaccine technology, which targets the -lactalbumin protein, a promising approach for immunoprevention strategies against breast cancer [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a strong emphasis on developing next-generation preventive immunotherapies [2][5] - The company has a collaboration with Cleveland Clinic for the development of its breast cancer vaccine, which is part of a broader portfolio that includes ovarian cancer immunotherapy [5] Patent and Intellectual Property - The U.S. Patent Number 12,472,205 will be issued on November 18, 2025, extending the intellectual property protection for Anixa's breast cancer vaccine technology into the mid-2040s [1][2] - This patent reinforces the company's commitment to addressing breast cancer, which is projected to affect nearly 300,000 women in the U.S. by 2026 [1][3] Market Need - Breast cancer remains the most commonly diagnosed cancer among women globally, with over 297,000 new cases expected in the U.S. in 2025 and approximately 43,000 deaths anticipated [3] - There is currently no FDA-approved vaccine for breast cancer prevention, highlighting a significant unmet need in preventive oncology [3] Vaccine Mechanism - Anixa's investigational vaccine aims to stimulate the immune system to recognize and eliminate cells expressing -lactalbumin while sparing normal tissue, potentially minimizing off-target effects [4]

Core Insights - Anixa Biosciences has completed the final patient visit in its breast cancer vaccine clinical trial, marking a significant milestone in the first-in-human evaluation of the vaccine [1][3] - The vaccine aims to stimulate the immune system to recognize and target breast cancer before recurrence or development [2] - Preliminary results indicate that over 70% of participants demonstrated immune responses, suggesting the vaccine is well tolerated [4] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is developing vaccines for breast and ovarian cancer in partnership with Cleveland Clinic, which has exclusive licensing rights to these technologies [5] - Anixa's business model involves partnering with leading research institutions to explore emerging technologies for cancer treatment [5] Clinical Trial Details - The Phase 1 trial included 35 women across three cohorts: 26 in the TNBC group, 4 in the Prevention group, and 5 in the Pembrolizumab group [2][6] - Comprehensive data analysis will follow the completion of patient visits, with results to be submitted to the Department of Defense and the FDA [3] - Full clinical results are scheduled to be presented at the San Antonio Breast Cancer Symposium on December 11, 2025 [3]

Core Insights - Anixa Biosciences has initiated the transfer of the Investigational New Drug (IND) application for its breast cancer vaccine, which is currently held by Cleveland Clinic, to advance to a Phase 2 clinical trial [1][2][4] - The Phase 1 clinical trial has shown promising results, with over 70% of patients exhibiting immune responses, indicating the vaccine's potential effectiveness [2][4] - The breast cancer vaccine targets α-lactalbumin, a protein associated with lactation that re-emerges in many breast cancer forms, suggesting both therapeutic and preventive benefits [3][4] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is developing vaccines for breast and ovarian cancer, as well as other cancers, utilizing technologies that target proteins expressed in certain cancer forms [5] - Anixa's business model involves partnerships with leading research institutions to explore and commercialize emerging technologies in cancer treatment [5]

Core Insights - Anixa Biosciences has received a Notice of Allowance for a new patent in Canada related to its breast cancer vaccine technology, enhancing its international intellectual property portfolio [1][2][3] - The patent provides composition-of-matter protection for Anixa's immunogenic approach to breast cancer prevention and treatment, which is exclusively licensed from Cleveland Clinic [1][4] - Breast cancer is the most commonly diagnosed cancer in women globally, accounting for approximately 25% of new cancer cases in women in Canada and 13% of female cancer deaths annually [3] Intellectual Property Expansion - The newly allowed Canadian patent complements existing and pending patents in the United States and other key global jurisdictions, reinforcing Anixa's leadership in cancer immunoprevention [2][5] - This expansion of the patent estate is crucial for future regulatory and commercial efforts outside the U.S., positioning the company for strategic global opportunities [2][3] Vaccine Technology - Anixa's breast cancer vaccine targets human α-lactalbumin, a protein aberrantly expressed in certain breast cancers, aiming to prime the immune system to prevent tumor formation while sparing normal tissue [4][5] - The company's broader vaccine platform also addresses other high-incidence cancers, transforming the approach to cancer prevention in the medical community [5] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [6] - The company partners with renowned research institutions to develop vaccines targeting various cancers, including breast and ovarian cancer, utilizing a unique business model that allows for continuous examination of emerging technologies [6]